research Polymer conjugated retinoids for controlled transdermal delivery
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
Search
for
Sort by
Research
120-150 / 1000+ results
research Female pattern alopecia: current perspectives
Female pattern hair loss is caused by multiple factors and while treatments like topical minoxidil, hormone therapy, and low-level light therapy can help, none can fully cure it.
research Design and Validation of a Sensitive Multisteroid LC-MS/MS Assay for the Routine Clinical Use: One-Step Sample Preparation with Phospholipid Removal and Comparison to Immunoassays
The new LC-MS/MS method is more accurate and reliable than traditional immunoassays for measuring steroids in serum.
research Eyebrow and Eyelash Transplantation Using Chalazion Forceps (Dr. Min’s Method) and Importance of Post-Transplant Recovery in Hair Restoration
Dr. Min's method for eyebrow and eyelash transplantation is effective, with most hairs regrowing, and proper recovery is crucial for success.
research Androgenetic Alopecia in Men: An Update On Genetics
Androgenetic alopecia in men is genetic and linked to health issues like obesity and heart disease, with treatments including minoxidil, finasteride, and hair transplants.
research The relative effect of monotherapy with 5‐alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta‐analysis study
Finasteride 5mg daily is the most effective for female pattern hair loss, with higher doses of treatments generally more effective.
research Estrogens
research Hair Transplant
research Arzneimitteltherapie der Alopezien
Finasteride and minoxidil are effective for hair loss, with potential side effects, and JAK inhibitors show promise for alopecia areata.
research Guidelines based management of androgenetic alopecia
The document concludes that personalized treatment plans for hair loss in Asian men are necessary and more research is needed to develop effective guidelines.
research Female pattern hair loss: therapeutic update
Topical minoxidil is the best-supported treatment for female hair loss, but personalized plans are needed.
research Mandibulofacial dysostosis with alopecia results from ETAR gain-of-function mutations via allosteric effects on ligand binding
Specific mutations in a receptor cause facial abnormalities and hair loss.
research The triacylglycerol synthesis enzyme DGAT1 also catalyzes the synthesis of diacylglycerols, waxes, and retinyl esters
DGAT1 enzyme helps make diacylglycerols, waxes, and retinyl esters.
research Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study
Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research 058 The pattern of Fas and Fas ligand expression in alopecia areata
The Fas/FasL pathway may play a role in alopecia areata.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO)
The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
research Safety and efficacy of tofacitinib in 97 alopecia areata patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
research The Clinical Efficacy and Mechanism of Action of Alitretinoin in the Treatment of Alopecia Areata
Alitretinoin may help treat mild to moderate alopecia areata.
research Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
research Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Decision letter: Arabidopsis formin 2 regulates cell-to-cell trafficking by capping and stabilizing actin filaments at plasmodesmata
Arabidopsis Formin 2 stabilizes actin filaments to aid cell-to-cell trafficking.
research Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.